| Identification | Back Directory | [Name]
N-desMethyl EnzalutaMide | [CAS]
1242137-16-1 | [Synonyms]
CS-1325
N-desmethyl MDV3100
N-desmethyl MDV-3100
N-desmethyl MDV 3100
Enzalutamide Impurity R
Enzalutamide impurity O
Enzalutamide impurity B
Enzalutamide Impurity 2
N-desMethyl EnzalutaMide
Enzaluramide Impurities 2?
Enzalutamide N-Desmethyl Impurity
N-desmethyl MDV3100, N-desmethyl-Enzalutamide
N-DESMETHYL MDV3100;N-DESMETHYL MDV 3100;N-DESMETHYL MDV-3100
4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluorobenzaMide
Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro- | [Molecular Formula]
C20H14F4N4O2S | [MDL Number]
MFCD24386671 | [MOL File]
1242137-16-1.mol | [Molecular Weight]
450.41 |
| Chemical Properties | Back Directory | [Melting point ]
>230oC (dec.) | [Boiling point ]
572.4±60.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Amber Vial, Refrigerator | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated) | [form ]
Solid | [pka]
14.86±0.50(Predicted) | [color ]
White to Off-White | [Stability:]
Light Sensitive |
| Hazard Information | Back Directory | [Uses]
N-desMethyl EnzalutaMide is used in the treatment of disorders involving androgen, estrogen and progesterone receptors.
| [Definition]
ChEBI: N-desmethylenzalutamide is a benzamide obtained by formal condensation of the carboxy group of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluorobenzoic acid with ammonia. It has a role as an antineoplastic agent and an androgen antagonist. It is a member of benzamides, an imidazolidinone, a nitrile, a thiocarbonyl compound, a member of (trifluoromethyl)benzenes and a member of monofluorobenzenes. | [in vivo]
N-desmethyl Enzalutamide is an active metabolite that is thought to contribute to the clinical effects of Enzalutamide because it demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as Enzalutamide. The carboxylic acid metabolite is pharmacologically inactive and circulates at approximately 25 % lower plasma concentrations than Enzalutamide[1]. |
|
|